BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31233201)

  • 21. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
    Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
    Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. E2F1-induced ferritin heavy chain 1 pseudogene 3 (FTH1P3) accelerates non-small cell lung cancer gefitinib resistance.
    Zheng G; Chen W; Li W; Ding Y; Tu P; Chen W
    Biochem Biophys Res Commun; 2020 Oct; 530(4):624-631. PubMed ID: 32762943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression Profiles of microRNAs in Drug-Resistant Non-Small Cell Lung Cancer Cell Lines Using microRNA Sequencing.
    Hu S; Yuan Y; Song Z; Yan D; Kong X
    Cell Physiol Biochem; 2018; 51(6):2509-2522. PubMed ID: 30557872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy.
    Xiao Y; Yin C; Wang Y; Lv H; Wang W; Huang Y; Perez-Losada J; Snijders AM; Mao JH; Zhang P
    Mol Oncol; 2018 Jun; 12(6):883-895. PubMed ID: 29633504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of miR-143 overexpression on proliferation, apoptosis, EGFR and downstream signaling pathways in PC9/GR cell line.
    Dong YZ; Hu T
    Eur Rev Med Pharmacol Sci; 2018 Mar; 22(6):1709-1716. PubMed ID: 29630116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.
    La Monica S; Madeddu D; Tiseo M; Vivo V; Galetti M; Cretella D; Bonelli M; Fumarola C; Cavazzoni A; Falco A; Gervasi A; Lagrasta CA; Naldi N; Barocelli E; Ardizzoni A; Quaini F; Petronini PG; Alfieri R
    J Thorac Oncol; 2016 Jul; 11(7):1051-63. PubMed ID: 27006151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation.
    Hu Y; Qin X; Yan D; Cao H; Zhou L; Fan F; Zang J; Ni J; Xu X; Sha H; Liu S; Yu S; Wu J; Ma R; Feng J
    Tumour Biol; 2017 Mar; 39(3):1010428317691659. PubMed ID: 28345454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heptadecanoic acid inhibits cell proliferation in PC‑9 non‑small‑cell lung cancer cells with acquired gefitinib resistance.
    Xu C; Wu P; Gao J; Zhang L; Ma T; Ma B; Yang S; Shao G; Yu Y; Huang X; Yang X; Zhang B
    Oncol Rep; 2019 Jun; 41(6):3499-3507. PubMed ID: 31002344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
    Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
    Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long‑term exposure to gefitinib induces acquired resistance through DNA methylation changes in the EGFR‑mutant PC9 lung cancer cell line.
    Terai H; Soejima K; Yasuda H; Sato T; Naoki K; Ikemura S; Arai D; Ohgino K; Ishioka K; Hamamoto J; Kanai Y; Betsuyaku T
    Int J Oncol; 2015 Jan; 46(1):430-6. PubMed ID: 25353970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
    Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway.
    Zhou J; Qu G; Zhang G; Wu Z; Liu J; Yang D; Li J; Chang M; Zeng H; Hu J; Fang T; Song Y; Bai C
    J Exp Clin Cancer Res; 2019 Feb; 38(1):96. PubMed ID: 30791926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Sin TK; Wang F; Meng F; Wong SC; Cho WC; Siu PM; Chan LW; Yung BY
    Int J Mol Sci; 2016 Feb; 17(2):237. PubMed ID: 26891293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic activation of FOXF1 confers cancer stem cell properties to cisplatin‑resistant non‑small cell lung cancer.
    Zhao J; Xue X; Fu W; Dai L; Jiang Z; Zhong S; Deng B; Yin J
    Int J Oncol; 2020 May; 56(5):1083-1092. PubMed ID: 32319573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
    Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
    Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. miR-543 is up-regulated in gefitinib-resistant non-small cell lung cancer and promotes cell proliferation and invasion via phosphatase and tensin homolog.
    Bi M; Chen W; Yu H; Wang J; Ding F; Tang DJ; Tang C
    Biochem Biophys Res Commun; 2016 Nov; 480(3):369-374. PubMed ID: 27769862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vorinostat enhances gefitinib‑induced cell death through reactive oxygen species‑dependent cleavage of HSP90 and its clients in non‑small cell lung cancer with the EGFR mutation.
    Park SE; Kim DE; Kim MJ; Lee JS; Rho JK; Jeong SY; Choi EK; Kim CS; Hwang JJ
    Oncol Rep; 2019 Jan; 41(1):525-533. PubMed ID: 30365122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOXO3-induced oncogenic lncRNA CASC9 enhances gefitinib resistance of non-small-cell lung cancer through feedback loop.
    Bing Z; Han J; Zheng Z; Liang N
    Life Sci; 2021 Dec; 287():120012. PubMed ID: 34619168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.